iotaSciences and Quantum Design China Enter into Distribution Agreement
07 September 2023 | Thursday | News
Exclusive partnership will provide access for customers in China to iotaSciences proprietary single cell handling platforms based on its proprietary fluid-shaping technology
Image Source : Public Domain
iotaSciences, the Oxford-based leader in the rapidly growing field of single-cell handling solutions, and Quantum Design China, a subsidiary of Quantum Design International, announced today an exclusive distribution agreement for iotaSciences proprietary single cell handling platforms in China.
"We are pleased to now offer customers in China access to iotaSciences platforms, which allows scientists to access highly user-friendly, reliable, and powerful single cell handling technologies and solutions with unique capabilities that greatly simplify and facilitate breakthrough advances in cell biology and gene therapy" said Lambert Cao, General Manager of Quantum Design China. "We look forward to working closely with the iotaSciences team to introduce this unique technology to the rapidly expanding field of single cell biological applications."
Ed Walsh, iotaSciences Founding Director & Chief Innovation Officer commented: "We are highly excited about this next step with Quantum Design China to see our innovative technology being deployed across the Chinese scientific community. Our proprietary fluid-shaping technology has translated very well into tangible user benefits for single-cell handling workflows as required in many frontiers research fields including CRISPR, iPSCs and gene therapy workflows."
Dr. Michael Lutz, iotaSciences recently appointed CEO added: "This partnership with Quantum Design China is another key milestone for the company´s future development path after the recent acceleration of its commercial activities leading to a doubling of its installed base in the last year. Quantum Design China is the ideal partner for us to team up with given its in-depth knowledge of optimally serving academic and industrial scientists in the life science market in China."
Most Read
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
